The Readout Loud 384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
41 snips
Jan 14, 2026 Mike Doustdar, the new CEO of Novo Nordisk, shares insights on his first months at the helm, focusing on the challenge of reclaiming market share in obesity treatments. He discusses a patient-first acquisition strategy and Novo’s recent $10B bid for Metsera. Venture capitalist Bob Nelsen reflects on the importance of relationships in biotech at the J.P. Morgan conference, advocating for faster FDA approvals and the integration of AI in healthcare. Both guests offer exciting glimpses into the future of biotech and the evolving landscape of patient care.
AI Snips
Chapters
Transcript
Episode notes
Hedge Channels: Insurer Plus DTC
- Doustdar recommended mastering both insurer and direct-to-consumer channels rather than choosing one.
- He said meet patients where they are via partnerships and e-health to scale access fast.
Cash Channels Will Rise With System Strain
- Doustdar predicted cash channels will grow as healthcare systems strain under rising drug costs.
- He argued companies must master both reimbursement and cash paths to expand access sustainably.
JPM Became About Relationships
- Bob Nelsen said JPM evolved from deal-focused to relationship-focused for him.
- He added that now the conference is more about reconnecting than transaction hunting.